Peripheral Neuropathies, Osteoarthritis
Conditions
Keywords
Pain
Brief summary
The purpose of this clinical trial conducted in patients suffering from chronic pain is to study the relationship between individual patients' profile and their analgesic response
Interventions
BEHAVIORALHeat Pain Stimuli A
BEHAVIORALHeat Pain Stimuli B
BEHAVIORALPositive Video
BEHAVIORALNeutral Video
This treatment is given as add-on therapy to patient's regular analgesic treatment
This treatment is given as add-on therapy to patient's regular analgesic treatment
Sponsors
International Drug Development Institute
Tools4Patient
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Are men or women of at least 18 years of age * Diagnosed with Peripheral Neuropathic Pain (PNP) or knee or hip pain attributed to Osteoarthritis (OA) since at least 6 months * Affiliated with national welfare * Reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures * Have given written informed consent approved by the relevant Ethics Committee (EC) governing the study sites * Patients will be required to report pain with a score between 4 and 8 inclusive on the mean Average Pain Score (APS) during the baseline period preceding randomization and to have completed at least 10 days of pain assessments in their diary between Visit 1 and Visit 2. If more than 10 days were completed, the mean APS will be calculated on the last 10 ones. Inclusion Disease Criteria: * Diagnosis criterium for PNP: Patient with chronic PNP supported by a distinct neuroanatomical plausible distribution with sensory signs and symptoms, and consecutive to one of the following causes: a traumatic event, a surgical procedure (excluding limb amputation), radiculopathy, post- herpetic or post- zoster neuralgia, diabetic polyneuropathy or post chemotherapy. Diagnosis will have to be confirmed by the DN4 questionnaire at the screening visit (pain is considered as neuropathic if DN4 score ≥ 4) * Diagnosis criterium for OA: Patient with a unilateral or bilateral OA of the knee or hip diagnosed according to the American College of Rheumatology (ACR) criteria based on clinical and radiographic evidence (Altman et al. 1986). The clinical diagnosis of OA will be confirmed by the ACR clinical and radiographic criteria for classification of idiopathic OA of the knee or hip based upon the following criteria: 1. Knee or hip pain as an average at least half of the time for the last 3 months before screening visit 2. At least 1 of the following 3 conditions: Age \> 50 or morning stiffness \< 30 minutes or crepitus 3. Kellgren and Lawrence grade \> 1 as assessed if possible by an X-ray of the referred joint to confirm the diagnosis. If considered medically required by the Investigator based on patient needs and as part of regular patient management, a new anterior-posterior view X- ray should be obtained and reviewed by Investigator or his delegates to verify that the patient meets the disease diagnostic criteria
Exclusion criteria
* Patient changed his/her regular analgesic therapy for PNP or OA in the last 4 weeks prior to Visit 1 or during the study. * Patient's regular analgesic treatment for PNP or OA consists of more than 2 different treatments, with neurostimulation being considered as an analgesic treatment for PNP. * Patient reported unvariable APS and WPS scores between Visit 1 and Visit 2 (systematically the same APS score and the same WPS score reported). * Use or plan to use non-topical corticosteroids during the study. * Have initiated (or plan to initiate) a program (or modify an existing program in frequency and/or intensity) of physiotherapy or behavioral therapy such as pain self-management, hypnosis, sophrology, meditation program within 2 weeks prior to Visit 1 or during the study. * Pregnant, breastfeeding, or willing to be pregnant within 3 months. * Patients with a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere with the patient's participation in the study. * Uncontrolled epilepsy. * Any current primary psychiatric condition, including depression or personality disorders (such as Axe II of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV); personality disorders and mental retardation). * Alcohol dependence or regular use of known drugs of abuse (e.g., amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, and phencyclidine). * Any other relevant medical disorder/acute disease state judged by the Investigator as likely to interfere with the trial or represent a risk for the patient. * Any close relationship with the Investigators or the Sponsor (i.e. belonging to immediate family or subordination link). * Patient under legal protection, according to the national law. * Are persons who have previously received T4P1001, have completed or withdrawn from this study or any other study investigating T4P1001. * Patient currently enrolled in a clinical trial involving use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study, or in an exclusion period according to the national law. Exclusion Disease Criteria for PNP patients: * Neuropathic pain due to trigeminal neuralgia, central pain or phantom limb pain. * Have initiated, are planning to initiate an electrical stimulation (or neurostimulation) therapy or modify an existing neurostimulation within 4 weeks prior to Visit 1 or during study period. Exclusion disease criteria for OA patients: * Non-ambulatory due to OA. * Use of lower extremity assistive devices other than a cane such as crutches or walker or a knee brace or a shoe lift in relation to OA. * Have used in relation to OA systemic corticosteroids 4 weeks prior to Visit 1; Intra-muscular corticosteroid injections or Intra-articular injection of steroids into the referred knee/hip within 3 months before Visit 1, Intra-articular injection of corticosteroids into any other sites than the referred knee/hip within 4 weeks prior to Visit 1(corticosteroids in topical use are allowed). * Have used viscosupplementation or intra articular injection of hyaluronic acid in the referred joint within 3 months prior to Visit 1.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Average Pain Scores (APS) During 4 Weeks of Treatment | Time zero equals baseline (Day-28 to Day-14) up to Day 36 | 11-point Numeric Rating Scale (NRS); the 11 NRS scale ranges from 0 (No pain) to 10 (pain as bad as you can imagine); the baseline APS (weekly mean of the daily average pain score) was computed on the 7 last days before Visit 2 with available APS values; similarly, the end-of-treatment APS (or APS Week 4) was computed on the 7 last days before Visit 4 with available APS values. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient's Change From Baseline of Pain Severity as Measured by the Brief Pain Inventory (BPI) | Time zero equals baseline (Day-28 to Day-14) up to Day 29 | BPI is a self-reported scale that measures the severity of pain and the interference of pain on function (Charles S. Cleeland © 2009). In the short form of BPI, there are 4 questions assessing worst pain, least pain, actual pain and average pain in the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as bad as you can imagine). There are 7 questions assessing the interference of pain in the past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. The interference scores range from 0 (does not interfere) to 10 (completely interferes). |
| Patient's Change From Baseline of Investigator and Patient Global Assessment of Changes (IGAC and PGAC) | Time zero equals baseline (Day-28 to Day-14) up to Day 29 | IGAC and PGAC are subjective evaluations using a NRS with 0 meaning best condition and 10 worst condition |
| Patient's Change From Baseline of Heat Pain Threshold From Baseline to End of Treatment | Time zero equals baseline (Day 1) up to Day 29 | celcius degree, arithmetic average of 6 tests. |
| For Osteoarthritic Patients Only: Patient's Change From Baseline of Osteoarthritic Physical Function, Pain and Stiffness as Assessed by Western Ontario and MacMaster (WOMAC) Scales From Baseline to End of Treatment | Time zero equals baseline (Day-28 to Day-14) up to Day 29 | The WOMAC (Bellamy et al., 1988) is a patient-rated instrument that measures OA symptoms. The questionnaire contains 5 pain questions, 2 stiffness questions, and 17 physical function questions (24 questions total). Each question utilizes a 5-points Numeric Rating Scale (NRS) between 0-4; from 0=none to 4=extreme. Range of possible subscale scores: pain=0-20, stiffness=0-8 and physical function=0-68; higher scores for each subscale indicate worse outcomes. The WOMAC was completed at each Visit except for Visit 5 by OA patients only. |
Countries
Belgium, France
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| T4P1001 Heat Pain Stimuli A
Positive Video
Administration of T4P1001 capsules: This treatment is given as add-on therapy to patient's regular analgesic treatment | 57 |
| Placebo Heat Pain Stimuli B
Neutral Video
Administration of Placebo capsules: This treatment is given as add-on therapy to patient's regular analgesic treatment | 53 |
| Total | 110 |
Baseline characteristics
| Characteristic | T4P1001 | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 59.9 years STANDARD_DEVIATION 11.2 | 62.4 years STANDARD_DEVIATION 12.1 | 61.1 years STANDARD_DEVIATION 11.7 |
| Sex: Female, Male Female | 27 Participants | 38 Participants | 65 Participants |
| Sex: Female, Male Male | 30 Participants | 15 Participants | 45 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 14 / 58 | 13 / 56 |
| serious Total, serious adverse events | 0 / 58 | 1 / 56 |
Outcome results
Primary
Patient's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Average Pain Scores (APS) During 4 Weeks of Treatment
11-point Numeric Rating Scale (NRS); the 11 NRS scale ranges from 0 (No pain) to 10 (pain as bad as you can imagine); the baseline APS (weekly mean of the daily average pain score) was computed on the 7 last days before Visit 2 with available APS values; similarly, the end-of-treatment APS (or APS Week 4) was computed on the 7 last days before Visit 4 with available APS values.
Time frame: Time zero equals baseline (Day-28 to Day-14) up to Day 36
Population: 3 patients who completed the study were excluded from the Analysis Population due to protocol violations. Therefore only 110 patients were included in the Analysis Population.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| T4P1001 | Patient's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Average Pain Scores (APS) During 4 Weeks of Treatment | 0.54 score on a scale | Standard Deviation 1.92 |
| Placebo | Patient's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Average Pain Scores (APS) During 4 Weeks of Treatment | 0.95 score on a scale | Standard Deviation 1.86 |
Secondary
For Osteoarthritic Patients Only: Patient's Change From Baseline of Osteoarthritic Physical Function, Pain and Stiffness as Assessed by Western Ontario and MacMaster (WOMAC) Scales From Baseline to End of Treatment
The WOMAC (Bellamy et al., 1988) is a patient-rated instrument that measures OA symptoms. The questionnaire contains 5 pain questions, 2 stiffness questions, and 17 physical function questions (24 questions total). Each question utilizes a 5-points Numeric Rating Scale (NRS) between 0-4; from 0=none to 4=extreme. Range of possible subscale scores: pain=0-20, stiffness=0-8 and physical function=0-68; higher scores for each subscale indicate worse outcomes. The WOMAC was completed at each Visit except for Visit 5 by OA patients only.
Time frame: Time zero equals baseline (Day-28 to Day-14) up to Day 29
Population: Only OA sub-population of patients were included in the Analysis Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| T4P1001 | For Osteoarthritic Patients Only: Patient's Change From Baseline of Osteoarthritic Physical Function, Pain and Stiffness as Assessed by Western Ontario and MacMaster (WOMAC) Scales From Baseline to End of Treatment | Pain | 2.32 score on a scale | Standard Deviation 3.62 |
| T4P1001 | For Osteoarthritic Patients Only: Patient's Change From Baseline of Osteoarthritic Physical Function, Pain and Stiffness as Assessed by Western Ontario and MacMaster (WOMAC) Scales From Baseline to End of Treatment | Stiffness | 0.93 score on a scale | Standard Deviation 1.59 |
| T4P1001 | For Osteoarthritic Patients Only: Patient's Change From Baseline of Osteoarthritic Physical Function, Pain and Stiffness as Assessed by Western Ontario and MacMaster (WOMAC) Scales From Baseline to End of Treatment | Physical function | 6.71 score on a scale | Standard Deviation 9.37 |
| Placebo | For Osteoarthritic Patients Only: Patient's Change From Baseline of Osteoarthritic Physical Function, Pain and Stiffness as Assessed by Western Ontario and MacMaster (WOMAC) Scales From Baseline to End of Treatment | Pain | 4.08 score on a scale | Standard Deviation 3.13 |
| Placebo | For Osteoarthritic Patients Only: Patient's Change From Baseline of Osteoarthritic Physical Function, Pain and Stiffness as Assessed by Western Ontario and MacMaster (WOMAC) Scales From Baseline to End of Treatment | Stiffness | 1.67 score on a scale | Standard Deviation 1.43 |
| Placebo | For Osteoarthritic Patients Only: Patient's Change From Baseline of Osteoarthritic Physical Function, Pain and Stiffness as Assessed by Western Ontario and MacMaster (WOMAC) Scales From Baseline to End of Treatment | Physical function | 13.67 score on a scale | Standard Deviation 11.53 |
Secondary
Patient's Change From Baseline of Heat Pain Threshold From Baseline to End of Treatment
celcius degree, arithmetic average of 6 tests.
Time frame: Time zero equals baseline (Day 1) up to Day 29
Population: 3 patients who completed the study were excluded from the Analysis Population due to protocol violations. Therefore only 110 patients were included in the Analysis Population.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| T4P1001 | Patient's Change From Baseline of Heat Pain Threshold From Baseline to End of Treatment | -0.05 °C | Standard Deviation 3 |
| Placebo | Patient's Change From Baseline of Heat Pain Threshold From Baseline to End of Treatment | -0.67 °C | Standard Deviation 3.26 |
Secondary
Patient's Change From Baseline of Investigator and Patient Global Assessment of Changes (IGAC and PGAC)
IGAC and PGAC are subjective evaluations using a NRS with 0 meaning best condition and 10 worst condition
Time frame: Time zero equals baseline (Day-28 to Day-14) up to Day 29
Population: 3 patients who completed the study were excluded from the Analysis Population due to protocol violations. Therefore only 110 patients were included in the Analysis Population.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| T4P1001 | Patient's Change From Baseline of Investigator and Patient Global Assessment of Changes (IGAC and PGAC) | PGAC | 1.11 score on a scale | Standard Deviation 2.25 |
| T4P1001 | Patient's Change From Baseline of Investigator and Patient Global Assessment of Changes (IGAC and PGAC) | IGAC | 0.96 score on a scale | Standard Deviation 1.82 |
| Placebo | Patient's Change From Baseline of Investigator and Patient Global Assessment of Changes (IGAC and PGAC) | PGAC | 2.04 score on a scale | Standard Deviation 1.93 |
| Placebo | Patient's Change From Baseline of Investigator and Patient Global Assessment of Changes (IGAC and PGAC) | IGAC | 1.83 score on a scale | Standard Deviation 1.9 |
Secondary
Patient's Change From Baseline of Pain Severity as Measured by the Brief Pain Inventory (BPI)
BPI is a self-reported scale that measures the severity of pain and the interference of pain on function (Charles S. Cleeland © 2009). In the short form of BPI, there are 4 questions assessing worst pain, least pain, actual pain and average pain in the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as bad as you can imagine). There are 7 questions assessing the interference of pain in the past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. The interference scores range from 0 (does not interfere) to 10 (completely interferes).
Time frame: Time zero equals baseline (Day-28 to Day-14) up to Day 29
Population: 3 patients who completed the study were excluded from the Analysis Population due to protocol violations. Therefore only 110 patients were included in the Analysis Population.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| T4P1001 | Patient's Change From Baseline of Pain Severity as Measured by the Brief Pain Inventory (BPI) | Pain | 0.98 score on a scale | Standard Deviation 1.63 |
| T4P1001 | Patient's Change From Baseline of Pain Severity as Measured by the Brief Pain Inventory (BPI) | Interference of pain | 1.09 score on a scale | Standard Deviation 1.93 |
| Placebo | Patient's Change From Baseline of Pain Severity as Measured by the Brief Pain Inventory (BPI) | Pain | 1.61 score on a scale | Standard Deviation 1.49 |
| Placebo | Patient's Change From Baseline of Pain Severity as Measured by the Brief Pain Inventory (BPI) | Interference of pain | 1.94 score on a scale | Standard Deviation 1.71 |